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INTRODUCTION
Lung cancer is the leading cause of death due to
malignant disease in the developed world. Despite
advances in variety of therapies, surgery is still the
best treatment option for patients with localized
non-small cell lung cancer (NSCLC) (1). For the re-
moval of the primary tumor, a surgical procedure
such as lobectomy, bilobectomy, and pneumonec-
tomy should be selected for the purpose of com-
plete resection. Although the role of segmentec-
tomy is being reconsidered for NSCLC of 2 cm or
less (2), lobectomy is still considered the procedure
of choice for patients even with peripheral T1N0
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NSCLC (3). For the removal of mediastinal lymph
nodes, many investigators insist on the importance
of systematic nodal dissection (SND) for accurate
staging (4-10).
To decide the adequate therapy for patients with
resectable NSCLC, a more accurate preoperative
evaluation is essential. Accuracy of CT in preop-
erative mediastinal lymph node staging was 45 to
79% (11-15). Recently, cervical mediastinoscopy or
positron emission tomography (PET) scanning with
2- (fluorine-18) fluoro-2-deoxy-D-glucose (FDG)
proved more accurate than computed tomography
(CT) in demonstration and staging of nodal involve-
ment (11-13). However, advancements in CT have
been allowing us to detect more detailed informa-
tion and CT is still widely used for assessment of
mediastinal involvement.
To clarify whether the effect of lymph node sam-
pling (LS) is equal to that of SND or not, we com-
pared the effect of LS with SND in patients with
clinical stage I (cT1 or cT2, and cN0) NSCLC.
MATERIALS AND METHODS
Patients
One hundred and nineteen consecutive patients
with clinical stage I NSCLC, who underwent curative
operation between January 1994 and December 2000
at Tokushima University Hospital and Takamatsu
Red Cross Hospital, were retrospectively reviewed
(SND = 58 : LS = 61). In this period, patients with
clinical stage I NSCLC underwent principally lobec-
tomy with SND at Tokushima University Hospital
and with LS at Takamatsu Red Cross Hospital. These
hospitals are related institutions, therefore the cri-
teria of preoperative examinations and diagnosis are
the same. Patients were preoperatively assessed by
chest x-ray, chest and upper abdomen CT scan,
brain MRI, and bone scintigraphy. Patients were in-
cluded into the study if they presented no lymph
node swelling in hilar and mediastinal lymph nodes,
and no evidence of distant metastasis. Hilar and
mediastinal lymph nodes more than 1cm in short-
axis diameter according to the CT scan were re-
garded as metastatic lymph nodes. Patients with
previous or coexistent malignant disease were ex-
cluded from the study. None of the patients in the
study received preoperative chemotherapy or radio-
therapy. Patients who underwent SND at Tokushima
University Hospital were included in the SND group,
and patients who underwent LS at Takamatsu Red
Cross Hospital were included in the LS group.
Surgical Procedures
For patients with SND, surgical approach was via
posterolateral thoracotomy in the fifth intercostal
space. For the patients with LS, surgical approach
was via small lateral thoracotomy in the fifth inter-
costal space with the use of thoracoscopy. The tech-
nique of resection of the primary lung cancer was
the same in both groups. Patients who underwent
segmentectomy or partial resection were excluded
from the study.
In the LS group, the resection was combined with
a regional lymph node dissection of interlobular,
peribronchial, and hilar nodes representing nodes
10, 11, and 12 according to the lymph node map-
ping proposed by Naruke, et al (16). A mediasti-
notomy was performed via longitudinal incision of
the mediastinal pleura, and nodes of regions 2 to 9
were explored. Any nodes showing evidence of can-
cer were removed and submitted for pathohistologic
analysis. However, no patient underwent periopera-
tive pathohistologic examination and converted from
LS to SND perioperatively. For right-sided tumors,
nodes of regions 3, 4, and 7, and for left-sided tu-
mors, nodes of regions 5, 6, and 7 were removed
routinely in all patients. Patients who underwent in-
adequate lymph node sampling were excluded from
the study.
In the SND group, resection was combined with
a radical systematic en bloc mediastinal lymph node
dissection as described by Naruke (17) and Martini
(18). Briefly, in right-sided tumors, the superior me-
diastinal compartment, contained between the tra-
chea, the superior vena cava from the level of the
azygos vein to the right subclavian artery, and the
right recurrent laryngeal nerve, was dissected and
the trachea, azygos vein, superior vena cava, and
ascending aorta were completely freed from all tis-
sue. The azygos vein and the vagus nerve were gen-
erally spared, and the right laryngeal nerve was ex-
posed. The anterior mediastinum anteriorly to the
superior vena cava was also routinely removed, in-
cluding the associated thymic tissue. Subcarinal,
paraesophageal, and inferior pulmonary lymph nodes
were removed en bloc. For sampling reasons, con-
tralateral hilar nodes were also excised. In left-sided
cancers, the subaortic compartment, contained be-
tween the left pulmonary artery, the aortic arch, the
left recurrent laryngeal, and the phrenic nerve, was
dissected by completely freeing the left vagal nerve
and the recurrent laryngeal nerve. Thereafter, the
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aortopulmonary ligament of Botalli was ligated and
divided and the aortic arch was mobilized anteri-
orly to facilitate dissection of paratracheal nodes
(nodes 3 and 4). Lymph node dissection in the in-
ferior mediastinum was performed similarly to that
on the right side. Routinely, contralateral hilar nodes
were removed for sampling.
Postoperative evaluations
The number of mediastinal lymph nodes was
counted according to the pathologic reports. Pa-
tients who postoperatively proved to have N2 dis-
ease underwent cis-diamminedichloroplatinum-based
adjuvant chemotherapy. Patients who did not leave
the hospitals after surgery or died from causes other
than the original NSCLC were excluded. Patient
follow up data were obtained by direct patient con-
tact at each hospital, or by replies to prognosis in-
vestigation mail. The follow-up data were obtained
through to May 2004.
Statistical Methods
Comparisons between patient characteristics were
made by Pearson’s chi square test. The numbers of
removed lymph nodes are expressed as mean and
meansstandard deviations. The student t test was
used to compare the number of removed lymph
nodes. The end point of this study was overall can-
cer specific survival, which was calculated from the
date of operation to that of death. Survival probabil-
ity was calculated by the Kaplan-Meier method. The
log-rank test was used to compare survivals between




Patient characteristics are listed in Table 1. There
was no significant difference in age, gender, his-
tologic type, clinical T stage, tumor location, and
surgical procedure between the two groups. All pa-
tients were treated by lobectomy or pneumonec-
tomy. The SND group included 2 bilobectomies
and 2 sleeve lobectomies, and the LS group included
2 bilobectomies and 1 pneumonectomy.
Table 1. Patient characteristics
SND (n = 58) LS (n = 61) p Value
Age 70yr 38 (65.5%) 39 (63.9%) 0.86
70yr 20 (34.5%) 22 (36.1%)
Gender Male 39 (67.2%) 32 (52.6%) 0.10
Female 19 (32.8%) 29 (47.4%)
Histologic Adenocarcinoma 44 (75.9%) 46 (75.4%) 1.00
type Squamous cell ca. 12 (20.7%) 13 (21.3%)
Others 2 (3.4%) 2 (3.3%)
Clinical cT1 42 (72.4%) 38 (62.3%) 0.24
T stage cT2 16 (27.6%) 23 (37.7%)
Tumor Right 38 (65.5%) 39 (63.9%) 0.86
location Left 20 (34.5%) 22 (36.1%)
Surgical Lobectomy 56 (96.6%) 58 (95.1%) 0.62
procedure Bilobectomy 2 (3.4%) 2 (3.3%)
Pneumonectomy 0 (0%) 1 (1.6%)
SND = systematic nodal dissection ; LS = lymph node sampling
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The number of removed mediastinal lymph nodes
We demonstrated the mean number of removed
lymph nodes at each station in Table 2. The total
number of removed mediastinal lymph nodes in pa-
tients who underwent SND was 22.19.7, which
was significantly higher than that in patients who
underwent LS of 11.4  7.0 (p  0.001). And the
number of mediastinal lymph nodes on both sides
was significantly higher in the SND group than in
the LS group.
Cancer specific survivals between the SND and the
LS
The median follow up time was 82 months in the
SND group, and 77 months in the LS group. The
cancer specific survival rate in the 119 patients at 5
years was 77.2%, and the 5-year survival rate in pa-
tients with pN0, pN1, and pN2 was 83.4%, 69.2%,
and 46.7%, respectively. The Kaplan-Meier survival
curves of the SND and the LS groups are depicted
in Figure 1, and 5-year survival rate was 78.0% in the
SND group and 76.2% in the LS group. There was
no significant difference between the two groups
(p = 0.60). Figure 2 and 3 show the survival curves
of clinical T1 and T2 cases, respectively. The sur-
vival rate in patients with cT1 who underwent SND
and LS at 5 year was 84.8% and 81.1%, respectively.
And, the survival rate in patients with cT2 who un-
derwent SND and LS at 5 year was 58.9% and 67.5%,
respectively. There was no significant difference in
survival of both T1 and T2 cases between the SND
and the LS groups.
Table 2. Number of removed mediastinal lymph nodes
Station No.









1 2.2 0.1 0.3
2
3 0.4





7 7.1 5.3 4.4 1.7
8 0.6 0.4 0.1 0.4
9 0.6 1.3 0.05 0.4
25.48.8 13.27.8 p0.001
total 16.28.9 8.44.3 p0.001
22.19.7 11.47.0 p0.001
Station numbers are classified according to Naruke’s number-
ing system (19)
Values are presented as means and meansstandard deviations.
“*including 2, 3, 3a, 3 p, and 4. **including 4 and 5.”
SND = systematic nodal dissection ; LS = lymph node sampling
Figure 1. Survival curves of patients treated with systematic
nodal dissection (SND) and lymph node sampling (LS).
Figure 3. Survival curves of clinical T2 patients treated with
systematic nodal dissection (SND) and lymph node sampling
(LS).
Figure 2. Survival curves of clinical T1 patients treated with
systematic nodal dissection (SND) and lymph node sampling
(LS).
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N stage migration
The number of patients who postoperatively
proved to be N1 was 5 (8.6%) in the SND group
and 8 (13.1%) in the LS group. The number of pa-
tients who proved to be N2 was 8 (13.8%) in the
SND group and 7 (11.5%) in the LS group. There
was no significant difference in these proportions
between the SND and the LS groups (Table 3).
There was no patient with N3 disease. There were
5 patients with single-level N2 disease in the SND
group and 4 patients with that in the LS group.
Survivals of subgroups of patients with different
pathological N stages
There was no significant difference in pN0 cases
between the SND group and the LS group, and the
5-year survival rate was 80.1% in the SND and 86.2%
in the LS group (Figure 4). For a small group of
pN1 and pN2 cases, though the 5-year survival rate
of 69.2% for patients who underwent SND was rela-
tively better than 5-year survival rate of 45.0% for
patients who underwent LS, there was also no sig-
nificant difference between two groups (p = 0.27,
Figure 5).
DISCUSSION
Many investigators have emphasized the impor-
tance of SND for patients with resectable NSCLC,
because its staging accuracy can contribute to pa-
tient selection for adjuvant therapy and prediction
of prognosis (4-10). However, there have been a
limited number of randomized prospective trials
that had compared SND with LS in patients with
NSCLC (4, 5, 19). Izbicki (4) and Wu (5) investi-
gated patients with a wide range of clinical stages
which included clinical stage I to IIIA, while Sugi
(19) investigated a rather limited population which
included patients with peripheral lung cancer smaller
than 2 cm in diameter. Therefore, the benefit of
SND for the patients with clinical stage I NSCLC is
still controversial.
In the present study, we found no significant dif-
ference in cancer specific survival between SND
and LS in patients with clinical stage I NSCLC. Sugi
and colleagues (19) reported that there was no sig-
nificant difference in recurrence rate or survival in
patients with NSCLC smaller than 2 cm in diame-
ter between SND and LS. Izbicki and colleagues
(4) also found that SND did not influence disease-
free or overall survival in patients with clinical N0
or N1, and M0 NSCLC compared to LS. These stud-
ies support our result. Although Wu and colleagues
(5) showed SND provided a significantly better
prognosis than LS in patients with pathological
stage I NSCLC, they did not show the result of
clinical stage I disease. Therefore, we consider that
the therapeutic effect of LS is equal to that of SND
in patients with clinical stage I NSCLC.
The number of removed mediastinal lymph nodes
in patients who underwent SND was significantly
higher than that in patients who underwent LS in
Figure 4. Survival curves of pathologic N0 patients treated
systematic nodal dissection (SND) and lymph node sampling
(LS).
Table. 3 N stage migration
SND (n = 58) LS (n = 61) p value
pN0 45 (77.6%) 46 (75.4%)
pN1 5 (8.6%) 8 (13.1%) 0.71
pN2 8 (13.8%) 7 (11.5%)
SND = systematic nodal dissection ;
LS = lymph node sampling
Figure 5. Survival curves of pathologic N1 and N2 patients
treated with systematic nodal dissection (SND) and lymph node
sampling (LS).
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our study (22.19.7 : 11.47.0, p 0.001). How-
ever, there was a strong similarity in the percent-
age of patients with pathological N1 or N2 disease
in both groups (SND : LS, pN1 ; 8.6% : 13.1%, pN2 ;
13.8% : 11.5%). Izbicki (4) and Sugi (19) also dem-
onstrated that the frequency of patients with pN1 or
pN2 disease was similar between SND and LS
groups. In the present study, we defined LS as rou-
tine removal of lymph node levels of 3, 4, and 7 for
right-sided tumors and 4, 5, and 7 for left-sided tu-
mors. Izbicki (4) and Sugi (19) defined the routine
removal of lymph node levels of 4, 5, and 7 as LS.
In patients with early stage NSCLC, cancer cells
are most likely to metastasize to lymph node level
3 and/or 4 in right upper lobe tumor, 3 and/or 7 in
right middle lobe tumor, 7 in right lower lobe tu-
mor, 5 and/or 6 in left upper lobe tumor, and 7 in
left lower lobe tumor (20). We considered that the
staging accuracy of LS is equal to that of SND in
clinical stage I NSCLC, if the proper extent of me-
diastinal lymph nodes were sampled during LS.
With the examination of the stage migration, sur-
vival according to the pathological stage, which may
be affected by spurious downstaging caused by in-
adequate staging, should be reviewed. Izbicki (4)
described that insufficiency in staging accuracy of
LS might have affected poorer outcome of small
group of patients with limited lymph node involve-
ment (pN1 disease or single-level pN2 disease). In
our study, there was no significant difference in
pN0 cases between the SND group and the LS
group. And for a small group of pN1 and pN2 cases,
there was also no significant difference between
two groups, though the 5-year survival rate of pa-
tients who underwent SND was relatively better
than that of patients who underwent LS.
We are well aware of two problems in our study.
One is that this is a retrospective study, and an-
other is that this study included patients in two hos-
pitals. However, there are personnel transactions
between the hospitals and the preoperative exami-
nations and diagnosis are extremely similar, be-
cause these hospitals are related institutions. More-
over, the scale of the hospitals is also similar, and
the patients in the two groups were well matched.
Therefore, any difference other than the treatment
for mediastinal lymph nodes was considered to be
minimal. Of course, our results do not have the
same strength as a randomized prospective trial,
however they provide a substantial basis for the
design of future randomized, prospective clinical
trials and treatment strategies.
Considering our result, a lobectomy with LS is
strategically acceptable for patients with clinical
stage I NSCLC. However, the patients who prove
to have mediastinal lymph node involvement by pe-
rioperative histopathologic examination had better
be converted from LS to SND, because it is still
unclear whether SND brings some therapeutic bene-
fits to the small group of pathological N2 patients.
In the near future, SND will become unnecessary
for patients with clinical stage I NSCLC with the
progress of pre and perioperative examinations,
which will provide more accurate staging. We found
11-14% of N2 disease in clinical stage I NSCLC,
when lymph nodes less than 1cm in diameter by CT
scan are regarded as node-negative. Several stud-
ies demonstrated that there are 12-17% of N2 posi-
tive patients who preoperatively diagnosed as N0 (4,
14, 15). And FDG-PET proved significantly more
accurate than CT in demonstrating and staging of
nodal involvement (12, 13). Recently, the technique
of perioperative sentinel node mapping, which can
identify nodal involvement at the first lymphatic
drainage site, has been developed, and this is ex-
pected to detect metastatic lymph nodes of the
mediastinum with a high accuracy rate (21, 22).
In conclusion, LS showed similar diagnostic and
therapeutic effects to SND in patients with clinical
stage I non-small cell lung cancer.
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